CRISPR THERAPEUTICS AG Total Liabilities
CRISPR THERAPEUTICS AG (CRSP) had Total Liabilities of $904.22 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-03
- 2026-06-30: Liabilities $904.22M.
- 2026-03-31: Liabilities $911.26M.
- 2025-12-31: Liabilities $343.43M.
- 2025-09-30: Liabilities $329.33M.
| Period end | Liabilities |
|---|---|
| 2026-06-30 | $904.22M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $911.26M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $343.43M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $329.33M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $318.59M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $336.94M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $309.95M 10-K · filed 2026-02-12 |
| 2024-09-30 | $316.47M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $358.90M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $355.08M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $346.77M 10-K · filed 2025-02-11 |
| 2023-09-30 | $359.04M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $380.99M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $389.47M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $367.58M 10-K · filed 2024-02-21 |
| 2022-09-30 | $399.40M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $372.53M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $361.26M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $352.42M 10-K · filed 2023-02-21 |
| 2021-09-30 | $308.80M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $295.72M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $152.41M 10-Q · filed 2021-04-27 |
| 2020-12-31 | $163.73M 10-K · filed 2022-02-15 |
| 2020-09-30 | $141.72M 10-Q · filed 2020-10-28 |
| 2020-06-30 | $135.86M 10-Q · filed 2020-07-27 |
| 2020-03-31 | $121.20M 10-Q · filed 2020-04-28 |
| 2019-12-31 | $127.33M 10-K · filed 2021-02-16 |
| 2019-09-30 | $128.71M 10-Q · filed 2019-10-28 |
| 2019-06-30 | $126.56M 10-Q · filed 2019-07-29 |
| 2019-03-31 | $118.06M 10-Q · filed 2019-04-29 |
| 2018-12-31 | $96.82M 10-K · filed 2020-02-12 |
| 2018-09-30 | $101.59M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $87.98M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $84.12M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $83.51M 10-K · filed 2019-02-25 |
| 2017-09-30 | $103.36M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $107.17M 10-Q · filed 2017-08-10 |
| 2017-03-31 | $107.17M 10-Q · filed 2017-05-11 |
| 2016-12-31 | $112.12M 10-K · filed 2018-03-08 |
| 2016-09-30 | $155.62M 10-Q · filed 2016-11-22 |
| 2015-12-31 | $124.03M 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |